{"transactions":[{"id":4622465,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622464,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":400,"price":65.31,"value":26124.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."}],"balance_after":87508,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622463,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":63.6865,"value":121004.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $63.6865, and the range of prices were between $63.59 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":87908,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622462,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":20735,"price":62.6079,"value":1298174.8065,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $62.6079, and the range of prices were between $62.38 and $63.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":89808,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622461,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":27473,"price":61.9969,"value":1703240.8337,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":110543,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":4622460,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T01:30:33.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":17.44,"value":348800.0,"ownership":{"direct":true},"balance_after":138016,"source":{"system":"sec-edgar","filing":"0001943192-26-000006","document":"form4-09182026_010929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000006/form4-09182026_010929.xml","form_type":"4"}},{"id":1918,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-03T20:05:20.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":642,"price":66.37,"value":42609.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":118016,"source":{"system":"sec-edgar","filing":"0001943192-26-000005","document":"form4-09032026_040908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1943192/000194319226000005/form4-09032026_040908.xml","form_type":"4"}},{"id":789848,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Performance-based restricted stock units","published_at":"2026-05-07T00:00:22.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."}],"balance_after":4250,"derivative":{"underlying":"Common  Stock","underlying_shares":4250},"source":{"system":"sec-edgar","filing":"0001943192-26-000004","document":"form4-05062026_080501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000004/form4-05062026_080501.xml","form_type":"4"}},{"id":789847,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Performance-based restricted stock units","published_at":"2026-05-07T00:00:22.000Z","date":"2026-05-04","kind":"grant","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."}],"balance_after":8500,"derivative":{"underlying":"Common  Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001943192-26-000004","document":"form4-05062026_080501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000004/form4-05062026_080501.xml","form_type":"4"}},{"id":789846,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-05-07T00:00:22.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":310,"price":43.95,"value":13624.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":118658,"source":{"system":"sec-edgar","filing":"0001943192-26-000004","document":"form4-05062026_080501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000004/form4-05062026_080501.xml","form_type":"4"}},{"id":789845,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-05-07T00:00:22.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":2181,"price":46.65,"value":101743.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":118968,"source":{"system":"sec-edgar","filing":"0001943192-26-000004","document":"form4-05062026_080501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000004/form4-05062026_080501.xml","form_type":"4"}},{"id":789844,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-05-07T00:00:22.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion."}],"balance_after":121149,"source":{"system":"sec-edgar","filing":"0001943192-26-000004","document":"form4-05062026_080501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000004/form4-05062026_080501.xml","form_type":"4"}},{"id":808129,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-16T01:46:57.000Z","date":"2026-04-15","kind":"sale","planned":true,"acquired":false,"shares":1014,"price":42.61,"value":43206.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":116899,"source":{"system":"sec-edgar","filing":"0001943192-26-000003","document":"form4-04162026_010454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000003/form4-04162026_010454.xml","form_type":"4"}},{"id":808128,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-16T01:46:57.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":7239,"price":41.9288,"value":303522.5832,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":117913,"source":{"system":"sec-edgar","filing":"0001943192-26-000003","document":"form4-04162026_010454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000003/form4-04162026_010454.xml","form_type":"4"}},{"id":808127,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-16T01:46:57.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":9,"price":41.07,"value":369.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":125152,"source":{"system":"sec-edgar","filing":"0001943192-26-000003","document":"form4-04162026_010454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000003/form4-04162026_010454.xml","form_type":"4"}},{"id":808126,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-16T01:46:57.000Z","date":"2026-04-13","kind":"sale","planned":true,"acquired":false,"shares":65,"price":28.85,"value":1875.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested  restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":125161,"source":{"system":"sec-edgar","filing":"0001943192-26-000003","document":"form4-04162026_010454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000003/form4-04162026_010454.xml","form_type":"4"}},{"id":808125,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-16T01:46:57.000Z","date":"2026-04-13","kind":"grant","planned":true,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS."}],"balance_after":125226,"source":{"system":"sec-edgar","filing":"0001943192-26-000003","document":"form4-04162026_010454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000003/form4-04162026_010454.xml","form_type":"4"}},{"id":917599,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-05T21:05:23.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":110,"price":32.9,"value":3619.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":111226,"source":{"system":"sec-edgar","filing":"0001943192-26-000002","document":"form4-02052026_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000002/form4-02052026_040201.xml","form_type":"4"}},{"id":917598,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-05T21:05:23.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":32.14,"value":52548.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $32.14, and the range of prices were between $31.645 and $32.645. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":111336,"source":{"system":"sec-edgar","filing":"0001943192-26-000002","document":"form4-02052026_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000002/form4-02052026_040201.xml","form_type":"4"}},{"id":921674,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2026-02-04T02:30:12.000Z","date":"2026-01-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":75000,"derivative":{"exercise_price":33.095,"expiration_date":"2036-01-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001943192-26-000001","document":"form4-02032026_090208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000001/form4-02032026_090208.xml","form_type":"4"}},{"id":921673,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-04T02:30:12.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":7242,"price":32.12,"value":232613.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":112971,"source":{"system":"sec-edgar","filing":"0001943192-26-000001","document":"form4-02032026_090208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000001/form4-02032026_090208.xml","form_type":"4"}},{"id":921672,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-04T02:30:12.000Z","date":"2026-01-31","kind":"grant","planned":false,"acquired":true,"shares":28130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":120213,"source":{"system":"sec-edgar","filing":"0001943192-26-000001","document":"form4-02032026_090208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319226000001/form4-02032026_090208.xml","form_type":"4"}},{"id":981401,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-12-03T21:30:13.000Z","date":"2025-12-01","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":16.23,"expiration_date":"2026-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001943192-25-000005","document":"form4-12032025_041209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319225000005/form4-12032025_041209.xml","form_type":"4"}},{"id":981400,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-12-03T21:30:13.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":35.0101,"value":700202.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016, with an expiration date of  May 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $35.0101, and the range of prices were between $34.64 and $35.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":92083,"source":{"system":"sec-edgar","filing":"0001943192-25-000005","document":"form4-12032025_041209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319225000005/form4-12032025_041209.xml","form_type":"4"}},{"id":981399,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-12-03T21:30:13.000Z","date":"2025-12-01","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":16.23,"value":324600.0,"ownership":{"direct":true},"balance_after":112083,"source":{"system":"sec-edgar","filing":"0001943192-25-000005","document":"form4-12032025_041209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000194319225000005/form4-12032025_041209.xml","form_type":"4"}},{"id":1046776,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-09-05T20:05:07.000Z","date":"2025-09-04","kind":"sale","planned":true,"acquired":false,"shares":119,"price":19.71,"value":2345.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":92083,"source":{"system":"sec-edgar","filing":"0001415889-25-023786","document":"form4-09052025_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925023786/form4-09052025_040901.xml","form_type":"4"}},{"id":1046775,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-09-05T20:05:07.000Z","date":"2025-09-03","kind":"sale","planned":true,"acquired":false,"shares":454,"price":18.2,"value":8262.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":92202,"source":{"system":"sec-edgar","filing":"0001415889-25-023786","document":"form4-09052025_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925023786/form4-09052025_040901.xml","form_type":"4"}},{"id":1053541,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-08-28T20:05:05.000Z","date":"2025-08-27","kind":"sale","planned":true,"acquired":false,"shares":470,"price":17.31,"value":8135.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in May 2025."}],"balance_after":92656,"source":{"system":"sec-edgar","filing":"0001415889-25-023209","document":"form4-08282025_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925023209/form4-08282025_040801.xml","form_type":"4"}},{"id":1159061,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Performance-based restricted stock units","published_at":"2025-05-06T01:54:31.000Z","date":"2025-05-02","kind":"exercise","planned":false,"acquired":false,"shares":4920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 1, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 1, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 1, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved."}],"balance_after":4920,"derivative":{"underlying":"Common  Stock","underlying_shares":4920},"source":{"system":"sec-edgar","filing":"0001415889-25-012061","document":"form4-05062025_010528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925012061/form4-05062025_010528.xml","form_type":"4"}},{"id":1159060,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-05-06T01:54:31.000Z","date":"2025-05-05","kind":"sale","planned":false,"acquired":false,"shares":1784,"price":21.05,"value":37553.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":93126,"source":{"system":"sec-edgar","filing":"0001415889-25-012061","document":"form4-05062025_010528.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925012061/form4-05062025_010528.xml","form_type":"4"}},{"id":1159059,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-05-06T01:54:31.000Z","date":"2025-05-02","kind":"exercise","planned":false,"acquired":true,"shares":4920,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 1, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each PSU represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":94910,"source":{"system":"sec-edgar","filing":"0001415889-25-012061","document":"form4-05062025_010528.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925012061/form4-05062025_010528.xml","form_type":"4"}},{"id":1172472,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-04-14T22:23:30.000Z","date":"2025-04-11","kind":"sale","planned":false,"acquired":false,"shares":48,"price":13.1446,"value":630.9408,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":89990,"source":{"system":"sec-edgar","filing":"0001415889-25-010643","document":"form4-04142025_100426.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925010643/form4-04142025_100426.xml","form_type":"4"}},{"id":1284573,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2025-02-05T01:30:11.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":58000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":58000,"derivative":{"exercise_price":20.46,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":58000},"source":{"system":"sec-edgar","filing":"0001415889-25-003062","document":"form4-02042025_080206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925003062/form4-02042025_080206.xml","form_type":"4"}},{"id":1284572,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-05T01:30:11.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":5192,"price":20.12,"value":104463.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":90038,"source":{"system":"sec-edgar","filing":"0001415889-25-003062","document":"form4-02042025_080206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925003062/form4-02042025_080206.xml","form_type":"4"}},{"id":1284571,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-05T01:30:11.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":95230,"source":{"system":"sec-edgar","filing":"0001415889-25-003062","document":"form4-02042025_080206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925003062/form4-02042025_080206.xml","form_type":"4"}},{"id":1296287,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-24T01:33:26.000Z","date":"2025-01-22","kind":"sale","planned":false,"acquired":false,"shares":865,"price":18.9409,"value":16383.8785,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":73730,"source":{"system":"sec-edgar","filing":"0001415889-25-001999","document":"form4-01242025_010121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925001999/form4-01242025_010121.xml","form_type":"4"}},{"id":1411805,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-10T01:20:05.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":2490,"price":11.52,"value":28684.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":74595,"source":{"system":"sec-edgar","filing":"0001415889-24-023091","document":"form4-09092024_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924023091/form4-09092024_090901.xml","form_type":"4"}},{"id":1411804,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-10T01:20:05.000Z","date":"2024-09-05","kind":"grant","planned":false,"acquired":true,"shares":6750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy."}],"balance_after":77085,"source":{"system":"sec-edgar","filing":"0001415889-24-023091","document":"form4-09092024_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924023091/form4-09092024_090901.xml","form_type":"4"}},{"id":1413790,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-06T01:30:05.000Z","date":"2024-09-04","kind":"sale","planned":false,"acquired":false,"shares":514,"price":9.5093,"value":4887.7802,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":70335,"source":{"system":"sec-edgar","filing":"0001415889-24-022992","document":"form4-09052024_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924022992/form4-09052024_090901.xml","form_type":"4"}},{"id":1542500,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-12T20:05:08.000Z","date":"2024-04-11","kind":"sale","planned":false,"acquired":false,"shares":54,"price":6.74,"value":363.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":70849,"source":{"system":"sec-edgar","filing":"0001415889-24-010754","document":"form4-04122024_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924010754/form4-04122024_040401.xml","form_type":"4"}},{"id":1661505,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee stock option (right to buy)","published_at":"2024-02-02T21:05:22.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":65000,"derivative":{"exercise_price":8.93,"expiration_date":"2034-01-30","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001415889-24-002280","document":"form4-02022024_040206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924002280/form4-02022024_040206.xml","form_type":"4"}},{"id":1661504,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-02T21:05:22.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":3818,"price":8.5313,"value":32572.5034,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the reported transaction was $8.5313, and the range of prices were between $8.5304 and $8.5315.  Upon request by the SEC staff, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":70903,"source":{"system":"sec-edgar","filing":"0001415889-24-002280","document":"form4-02022024_040206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924002280/form4-02022024_040206.xml","form_type":"4"}},{"id":1661503,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-02T21:05:22.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":74721,"source":{"system":"sec-edgar","filing":"0001415889-24-002280","document":"form4-02022024_040206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924002280/form4-02022024_040206.xml","form_type":"4"}},{"id":1670871,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-01-25T21:10:17.000Z","date":"2024-01-23","kind":"sale","planned":false,"acquired":false,"shares":853,"price":9.0684,"value":7735.3452,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":49721,"source":{"system":"sec-edgar","filing":"0001415889-24-001798","document":"form4-01252024_040102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924001798/form4-01252024_040102.xml","form_type":"4"}},{"id":1789083,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-06T00:15:39.000Z","date":"2023-09-05","kind":"sale","planned":false,"acquired":false,"shares":457,"price":14.7102,"value":6722.5614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":50574,"source":{"system":"sec-edgar","filing":"0001209191-23-048258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123048258/doc4.xml","form_type":"4"}},{"id":1894958,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-12T20:14:19.000Z","date":"2023-05-10","kind":"sale","planned":false,"acquired":false,"shares":455,"price":16.59,"value":7548.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":51031,"source":{"system":"sec-edgar","filing":"0001209191-23-029023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123029023/doc4.xml","form_type":"4"}},{"id":1920292,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-13T20:07:27.000Z","date":"2023-04-11","kind":"sale","planned":false,"acquired":false,"shares":47,"price":21.49,"value":1010.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":51486,"source":{"system":"sec-edgar","filing":"0001209191-23-024205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123024205/doc4.xml","form_type":"4"}},{"id":2035857,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-based restricted stock units","published_at":"2023-02-03T00:02:35.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":6750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date."}],"balance_after":6750,"derivative":{"underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0001209191-23-006422","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123006422/doc4.xml","form_type":"4"}},{"id":2035856,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2023-02-03T00:02:35.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":54500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":54500,"derivative":{"exercise_price":22.4,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":54500},"source":{"system":"sec-edgar","filing":"0001209191-23-006422","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123006422/doc4.xml","form_type":"4"}},{"id":2035855,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-03T00:02:35.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":1588,"price":21.752,"value":34542.176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":51533,"source":{"system":"sec-edgar","filing":"0001209191-23-006422","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123006422/doc4.xml","form_type":"4"}},{"id":2035854,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-03T00:02:35.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."}],"balance_after":53121,"source":{"system":"sec-edgar","filing":"0001209191-23-006422","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123006422/doc4.xml","form_type":"4"}},{"id":2044932,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-26T21:05:28.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":852,"price":21.9044,"value":18662.5488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":32871,"source":{"system":"sec-edgar","filing":"0001209191-23-005032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123005032/doc4.xml","form_type":"4"}},{"id":2168897,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-based restricted stock units","published_at":"2022-09-01T22:20:25.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":9840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31,2027 to the extent the specified performance based milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31,2027 to the extent the specified performance based milestones are not achieved by such date."}],"balance_after":9840,"derivative":{"underlying":"Common Stock","underlying_shares":9840},"source":{"system":"sec-edgar","filing":"0001209191-22-048347","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122048347/doc4.xml","form_type":"4"}},{"id":2168896,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock option (right to buy)","published_at":"2022-09-01T22:20:25.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":48000,"derivative":{"exercise_price":28.06,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001209191-22-048347","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122048347/doc4.xml","form_type":"4"}},{"id":2168895,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":1563,"kind":"person","name":"Cline Christopher R.","position":1,"cik":"0001943192","reported_name":"Cline Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-01T22:20:25.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The equity award vests over four years, with 1/4th vesting on each anniversary of the grant date."}],"balance_after":33723,"source":{"system":"sec-edgar","filing":"0001209191-22-048347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122048347/doc4.xml","form_type":"4"}}]}